New drug for moderate to severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have had moderate to severe atopic dermatitis (eczema) for at least 1 year.
- Your eczema should cover at least 10% of your body and be rated as moderate or severe by a doctor.
- You must have tried strong prescription creams or pills for eczema for at least 4 weeks (or 2 weeks for super-strong creams) before the trial.
- You cannot have any serious medical conditions like heart, liver, kidney problems, or cancer.
- You cannot have an active infection (like a lung or skin infection) within the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This study tests a new injected medication called XKH001 for people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't improved with standard creams. The goal is to see if it can reduce the severity of eczema and itching.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
This study tests an injection called ADSTEM for people with moderate to severe eczema (atopic dermatitis) that hasn't improved with standard creams or other treatments. The goal is to see if it can help reduce symptoms like itching and rash.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.